RhoE 精细调控心肌梗死炎症反应
该研究利用三种基因工程小鼠及分子实验,发现小 GTP 酶 RhoE 通过阻断 NF-κB 亚基核转位与异二聚化,抑制心肌梗死后过度炎症并改善心功能与生存;临床样本显示 RhoE 表达升高与心梗患者预后较好相关。
要点
- RhoE 在心肌梗死后表达上调,发挥抗炎保护作用
- RhoE 通过结合 p65/p50 阻断 NF-κB 核转位与二聚化
- 心肌细胞过表达 RhoE 可改善心功能与生存,或为预后标志物
核心结论
- RhoE 是调控心肌梗死后炎症的新精细调节因子,促进损伤心脏恢复。
- RhoE 可能作为评估心梗患者预后的新生物标志物及潜在治疗靶点。
研究设计与样本
- 使用三种基因小鼠:全局 RhoE 敲除、心肌细胞特异性 RhoE 杂合缺失、心肌细胞特异性 RhoE 过表达。
- 采用双分子荧光互补、免疫沉淀、电泳迁移率变动分析及 mRNA 微阵列等分子实验。
- 行左前降支永久结扎,评估 MI 后第一周心功能、炎症与生存。
- 检测 MI 患者心脏 RhoE 表达水平与预后相关性。
主要发现
- RhoE 缺失激活小鼠心脏一组促炎基因表达。
- 心肌细胞特异性单倍不足小鼠 MI 后炎症反应过度且心功能恶化。
- 突变心脏及分离心肌细胞中 NF-κB 活性显著增加。
- RhoE 在胞质中分别与 p65 和 p50 相互作用,阻断其核转位。
- RhoE 占据 p65 二聚化结构域,破坏 p65 与 p50 异二聚化。
临床怎么用
- RhoE 表达水平或可用于心梗患者预后评估。
- 调控 RhoE 可能成为 MI 及其他炎症性疾病的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory response after myocardial infarction (MI) is essential for cardiac healing, whereas excessive and prolonged inflammation extends the infarction and promotes adverse cardiac remodeling. Understanding the mechanistic insight of these tightly controlled inflammatory processes has a significant impact on post-MI recovery and therapy. Here, we uncover the critical role of small GTPase RhoE in post-MI recovery and its clinical implication. METHODS: Three genetic mouse lines are used: global RhoE knockout, cardiomyocyte-specific RhoE heterozygous, and cardiomyocyte-specific RhoE overexpression mice. A set of molecular signaling experiments, including bimolecular fluorescence complementation, immunoprecipitation, electrophoretic mobility shift assay, and mRNA microarray analysis, were conducted. Permanent ligation of the left anterior descending artery was performed, followed by the assessments of cardiac function, inflammation, and survival in the first week after MI. Finally, we examined the correlation of the expression levels of RhoE in MI patient heart and patient prognosis. RESULTS: RhoE deficiency turns on a group of proinflammatory gene expressions in mouse heart. Mice with cardiomyocyte-specific haploinsufficiency exhibit excessive inflammatory response with deleterious cardiac function after MI. A profound increase in nuclear factor-κB activity is detected in the mutant heart and the isolated cardiomyocytes. We further find that the expression of RhoE is upregulated in response to MI. Mechanistically, RhoE interacts with p65 and p50 individually in cytosol and blocks their nuclear translocation. RhoE also occupies the dimerization domain of p65 and subsequently disrupts the heterodimerization between p65 and p50. Cardiac RhoE overexpression inhibits nuclear factor-κB activity, restrains post-MI inflammation, and improves cardiac function and survival. Consistently, we find that the expression level of RhoE is elevated in the heart of patients with MI and that the patients with a higher expression level of RhoE exhibit a better prognosis in cardiac function recovery. CONCLUSIONS: The study uncovers RhoE as a new fine-tuning factor modulating MI-induced inflammation and promoting injured heart recovery. RhoE may serve as a new potential biomarker for the assessment of MI patient prognosis. Manipulation of RhoE could be as a potential therapeutic approach for MI and other inflammatory diseases.
引用
- Dai Y, Song J, Li W, et al. RhoE Fine-Tunes Inflammatory Response in Myocardial Infarction. Circulation. 2019. PMID: 30586715. doi:10.1161/CIRCULATIONAHA.118.033700
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。